07:39:49 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-26 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning SEZI 0.00 SEK
2024-05-16 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-28 Extra Bolagsstämma 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-17 Ordinarie utdelning SEZI 0.00 SEK
2023-05-16 Årsstämma 2023
2023-04-28 Kvartalsrapport 2023-Q1
2023-02-20 Bokslutskommuniké 2022
2023-02-16 Extra Bolagsstämma 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning SEZI 0.00 SEK
2022-05-18 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-12 Ordinarie utdelning SEZI 0.00 SEK
2021-05-11 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-03-05 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-15 Ordinarie utdelning SEZI 0.00 SEK
2020-05-14 Årsstämma 2020
2020-05-08 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-08-21 Extra Bolagsstämma 2019
2019-05-09 Ordinarie utdelning SEZI 0.00 SEK
2019-05-08 Kvartalsrapport 2019-Q1
2019-05-08 Årsstämma 2019
2019-02-15 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-09 Ordinarie utdelning SEZI 0.00 SEK
2018-05-08 Kvartalsrapport 2018-Q1
2018-05-08 Årsstämma 2018
2018-03-05 Extra Bolagsstämma 2018
2018-02-16 Bokslutskommuniké 2017
2017-11-28 Kvartalsrapport 2017-Q3
2017-09-15 Extra Bolagsstämma 2017
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-05-23 Årsstämma 2017
2017-02-16 Bokslutskommuniké 2016
2016-11-22 Kvartalsrapport 2016-Q3
2016-08-31 Kvartalsrapport 2016-Q2
2016-05-17 Extra Bolagsstämma 2016
2016-04-28 Ordinarie utdelning SEZI 0.00 SEK
2016-04-27 Kvartalsrapport 2016-Q1
2016-04-27 Årsstämma 2016
2016-02-18 Bokslutskommuniké 2015
2015-11-24 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-20 Ordinarie utdelning SEZI 0.00 SEK
2015-05-19 Årsstämma 2015
2015-05-19 Kvartalsrapport 2015-Q1
2015-02-25 Bokslutskommuniké 2014
2014-11-27 Kvartalsrapport 2014-Q3
2014-11-21 Extra Bolagsstämma 2014
2014-08-21 Kvartalsrapport 2014-Q2
2014-05-15 Ordinarie utdelning SEZI 0.00 SEK
2014-05-14 Kvartalsrapport 2014-Q1
2014-05-14 Årsstämma 2014
2014-02-24 Bokslutskommuniké 2013
2013-11-27 Kvartalsrapport 2013-Q3
2013-08-20 Kvartalsrapport 2013-Q2
2013-05-16 Ordinarie utdelning SEZI 0.00 SEK
2013-05-15 Kvartalsrapport 2013-Q1
2013-05-15 Årsstämma 2013
2013-02-28 Bokslutskommuniké 2012
2013-01-08 Extra Bolagsstämma 2013
2012-11-21 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-24 Ordinarie utdelning SEZI 0.00 SEK
2012-05-23 Årsstämma 2012
2012-05-23 Kvartalsrapport 2012-Q1
2012-02-22 Bokslutskommuniké 2011
2011-11-23 Kvartalsrapport 2011-Q3
2011-08-23 Kvartalsrapport 2011-Q2
2011-05-27 Ordinarie utdelning SEZI 0.00 SEK
2011-05-26 Kvartalsrapport 2011-Q1
2011-05-26 Årsstämma 2011
2011-02-16 Bokslutskommuniké 2010
2010-11-24 Kvartalsrapport 2010-Q3
2010-05-28 Ordinarie utdelning SEZI 0.00 SEK
2010-05-27 Kvartalsrapport 2010-Q1
2009-11-25 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Senzime är verksamt inom medicinteknik. Bolaget utvecklar medicintekniska lösningar som gör det möjligt att följa patienters biokemiska och fysiologiska processer inför, under och efter operation. I portföljen ingår system som används för att automatisera och mäta ämnena glukos och laktat i blod och vävnader. Utöver huvudverksamheten erbjuds även system för att övervaka patienters tillstånd under narkosbehandling. Bolagets huvudkontor ligger i Uppsala.
2022-08-01 11:00:00

Press release: Uppsala, 1 August 2022

Senzime AB (publ) (“Senzime” or the “Company”) publishes a prospectus for admission to trading of newly issued shares on Nasdaq Stockholm in connection with the acquisition of Respiratory Motion.

Today, Senzime publishes a prospectus prepared regarding admission to trading on Nasdaq Stockholm regarding the shares that have, and in the course of the period in which the prospectus is valid, may be issued in connection to the Company’s acquisition of the American company Respiratory Motion, Inc. (“Transaction” and "Respiratory Motion", respectively). The Transaction is described in more detail in the Company's press releases dated 1st June and 1st July 2022.

The initial consideration in the Transaction is 8,477,937 newly issued shares in Senzime (the “Consideration Shares”). Each of the sellers of Respiratory Motion must fulfil certain conditions in order to receive their share of the Consideration Shares. On 1st July 2022, Senzime’s Board of Directors resolved, as authorized by the extraordinary general meeting of 27th June 2022, on a directed issue of 2,127,537 shares to the sellers of shares in Respiratory Motion who, as of 1st July 2022, had fulfilled the conditions for receiving Consideration Shares.

The Board of Directors will continuously resolve on issues of Consideration Shares to the sellers of shares in Respiratory Motion who fulfil the conditions for obtaining Consideration Shares. The Board of Directors expects that all sellers will fulfil the conditions for obtaining Consideration Shares before 1st July 2023 and that all Consideration Shares will thus be issued in the course of the period in which the prospectus is valid. However, if all sellers do not fulfil the conditions for obtaining Consideration Shares in time, Senzime may issue less than 8,477,937 Consideration Shares.

Publication of prospectus
A prospectus has been prepared in connection with the admission to trading of the Consideration Shares issued on 1st July 2022 and the remaining Consideration shares that may be issued as payment of the initial purchase price in the Transaction. The prospectus has been approved today, 1st August 2022, by the Swedish Financial Supervisory Authority, SFSA. The prospectus is available on the Company’s website, www.senzime.com. The prospectus will also be available on SFSA’s website, www.fi.se.

Advisors
Carnegie is financial advisor, Eversheds Sutherland (Stockholm and Chicago) is legal advisor in connection with the acquisition of Respiratory Motion, and Advokatfirman Lindahl KB is legal advisor in connection with the issue of new shares and the preparation of the prospectus.

For further information, please contact:

Pia Renaudin, CEO
Tel: +46 70-813 34 17, email: pia.renaudin@senzime.com

About Senzime

Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq Stockholm (ticker SEZI). www.senzime.com

Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Senzime in any jurisdiction, neither from Senzime nor from anyone else.

Any investment decision in connection with the issue must be made on the basis of all publicly available information relating to the Company and the Company’s shares. Such information has not been independently verified by Carnegie. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied or distributed, directly or indirectly, in whole or in part, to Australia, Canada, Japan or the United States of America or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. Senzime has not authorized any offer to the public of shares or rights in any member state of the EEA. In any EEA Member State and in the United Kingdom, this communication is only addressed to and is only directed at qualified investors in that Member State or in the United Kingdom within the meaning of the Prospectus Regulation.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49 (2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

Information to distributors
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Senzime have been subject to a product approval process, which has determined that the shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares may decline and investors could lose all or part of their investment; the shares offer no guaranteed income and no capital protection; and an investment in the shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the share issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Senzime.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Senzime and determining appropriate distribution channels.

Forward-looking statements
To the extent this press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.